Literature DB >> 18305916

[Can the progression of chronic renal failure be delayed?].

U Kuhlmann1, J Hoyer.   

Abstract

Chronic renal failure does not only involve the risk for the patient of becoming dependent on hemodialysis, but also increases the risk of premature death due to cardiovascular events. In most renal diseases, progressive chronic loss of renal function develops once a critical extent of renal damage has occurred, independent of the course of the underlying renal disease. The key factors driving the progressive loss of renal function are, apart from the underlying nephrological disease, arterial hypertension and diabetes mellitus. The loss of renal function is also promoted by other factors, such as increased intake of dietary proteins, chronic inflammation, smoking, and anemia. With the help of a multimodal therapeutic concept, the progression of chronic renal failure can be delayed effectively. This approach comprises strict blood pressure control with a target blood pressure of 130/80 mmHg in patients with micro-albuminuria and of 120/75 mmHg in patients with proteinuria of >1 g/d. The preferred drugs for the treatment of hypertension are ACE inhibitors and angiotensin receptor blockers. In diabetics with renal insufficiency, target HbA1c levels below 7% are to be aimed for. Dietary protein intake should be restricted to 0.8-1 g/kg body weight/d. Additional therapeutic targets include nicotine abstinence, early treatment of renal anemia, weight reduction, and, if indicated, lipid-lowering therapy.

Entities:  

Mesh:

Year:  2008        PMID: 18305916     DOI: 10.1007/s00108-008-2023-1

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  16 in total

Review 1.  Epoetin treatment: what are the arguments to expect a beneficial effect on renal disease progression?

Authors:  Jerome Rossert; William M McClellan; Simon D Roger; Dierik L Verbeelen
Journal:  Nephrol Dial Transplant       Date:  2002-03       Impact factor: 5.992

Review 2.  Predicting initiation and progression of chronic kidney disease: Developing renal risk scores.

Authors:  M W Taal; B M Brenner
Journal:  Kidney Int       Date:  2006-09-13       Impact factor: 10.612

3.  Developmental hypertension, nephrogenesis, and mother's milk: programming the neonate.

Authors:  Susan P Bagby
Journal:  J Am Soc Nephrol       Date:  2007-05-18       Impact factor: 10.121

Review 4.  Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study.

Authors:  Giuseppe Remuzzi; Manuel Macia; Piero Ruggenenti
Journal:  J Am Soc Nephrol       Date:  2006-04       Impact factor: 10.121

Review 5.  Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses.

Authors:  Carlos Chiurchiu; Giuseppe Remuzzi; Piero Ruggenenti
Journal:  J Am Soc Nephrol       Date:  2005-03       Impact factor: 10.121

Review 6.  Lipid changes and statins in chronic renal insufficiency.

Authors:  Eberhard Ritz; Christoph Wanner
Journal:  J Am Soc Nephrol       Date:  2006-12       Impact factor: 10.121

7.  Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency.

Authors:  Fan Fan Hou; Di Xie; Xun Zhang; Ping Yan Chen; Wei Ru Zhang; Min Liang; Zhi Jian Guo; Jian Ping Jiang
Journal:  J Am Soc Nephrol       Date:  2007-05-09       Impact factor: 10.121

8.  Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study.

Authors:  J C Peterson; S Adler; J M Burkart; T Greene; L A Hebert; L G Hunsicker; A J King; S Klahr; S G Massry; J L Seifter
Journal:  Ann Intern Med       Date:  1995-11-15       Impact factor: 25.391

9.  Progression rate to end-stage renal failure in non-diabetic kidney diseases: a multivariate analysis of determinant factors.

Authors:  P Jungers; T Hannedouche; Y Itakura; G Albouze; B Descamps-Latscha; N K Man
Journal:  Nephrol Dial Transplant       Date:  1995       Impact factor: 5.992

10.  Blood pressure and end-stage renal disease in men.

Authors:  M J Klag; P K Whelton; B L Randall; J D Neaton; F L Brancati; C E Ford; N B Shulman; J Stamler
Journal:  N Engl J Med       Date:  1996-01-04       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.